Farcast announces ISO 9001 certification human Tumor Microdynamics (hTMD) platform

August 14, 2023 10:16 PM AEST | By EIN Presswire

Google News:

Farcast announces ISO 9001 certification human Tumor Microdynamics (hTMD) platform — Image source: Kalkine Media

Recent News

AN2 Therapeutics Reports Key Insights from 200-Patient Observational S...

Georgia Chamber Panel: Innovations in Georgia Forestry

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer's...

GIBO Click Powers Intelligent Monetization Trials on uDrama, Enhancing...

This certification is a testimony to our culture of quality and we will continue building it further across our future global centers.”

— Mohit Malhotra

PENSACOLA, FLORIDA, USA, August 14, 2023/EINPresswire.com/ -- Farcast Biosciences announces ISO 9001 certification of its human Tumor Microdynamics (hTMD) platform. German TÜV NORD, one of the world's largest inspection, certification & testing organization issued the certification covering the TruTumor culturing, pathology, assaying and data generation technologies. These technologies are a foundational element in Farcast’s platform for precision cancer research.

The certification ensures that compliance with standard procedures, documentation integrity, audit trails, training of staff, vendor management, and other regulatory requirements are vetted to the highest quality standards. Farcast’s mission is to make treatment with cancer therapeutics and diagnostics more predictable, its success depends on insights mined from the largest and most reliable datasets created from living human tumor tissue samples.

“This certification is a testimony to the maturity of our quality processes that we have developed and followed over the years. The quality of our data is a function of the consistency in the execution of our processes. We take pride in the culture of quality that we have built across all functions and levels at Farcast. Ours may be the only such technology with this certification in one of our main centers in India and we are committed to applying the same level of rigor in all our global centers in the future,” said Mohit Malhotra CEO and cofounder of Farcast.

Sanjay Virmani
Farcast Biosciences
+1 609-273-4174
[email protected]
Visit us on social media:
LinkedIn

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.